Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.52 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.52 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | STAT3 | P40763 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3342327 | 0.89 | MAPT (0.70) | MAPTRAB9AADRB2ADRB1ADRB3 | |
| SCHEMBL3345764 | 0.86 | RAB9A (0.51) | MAPTRAB9AADRB2ADRB1ADRB3 | |
| SCHEMBL27978531 | 0.85 | ADRB2 (0.58) | MAPTRAB9AADRB2ADRB1ADRB3 | |
| SCHEMBL4433890 | 0.79 | ADRB2 (0.51) | MAPTADRB2ADRB1ADRB3MAPK1 | |
| SCHEMBL6832454 | 0.78 | ADRB2 (0.52) | MAPTRAB9AADRB2ADRB1ADRB3 | |
| SCHEMBL3340223 | 0.76 | NPSR1 (0.56) | MAPTRAB9AMAPK1HTTKDM4E | |
| SCHEMBL16293426 | 0.76 | ADRB2 (0.51) | ADRB2ADRB1ADRB3STAT3 | |
| SCHEMBL3404456 | 0.75 | KMT2A (0.72) | MAPTRAB9AADRB2ADRB1ADRB3 | |
| SCHEMBL3340197 | 0.75 | LRRK2 (0.53) | MAPTADRB2ADRB1ADRB3MAPK1 | |
| SCHEMBL3339299 | 0.75 | ADRB2 (0.49) | MAPTADRB2ADRB1ADRB3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100063047-A1 | AMINOPYRIMIDINE INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063047-A1 | AMINOPYRIMIDINE INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH2, HRH3 | MAPT 2488/4885RAB9A 2578/4885ADRB2 882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.